Verastem Revenue and Competitors

Needham, MA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Verastem's estimated annual revenue is currently $17.1M per year.(i)
  • Verastem's estimated revenue per employee is $160,849

Employee Data

  • Verastem has 106 Employees.(i)
  • Verastem grew their employee count by 19% last year.

Verastem's People

NameTitleEmail/Phone
1
Chief StaffReveal Email/Phone
2
CEOReveal Email/Phone
3
Chief Medical OfficerReveal Email/Phone
4
Chief Operating OfficerReveal Email/Phone
5
Chief Information OfficerReveal Email/Phone
6
Head Communications and Patient AdvocacyReveal Email/Phone
7
VP, FinanceReveal Email/Phone
8
Head Safety and PharmacovigilanceReveal Email/Phone
9
SVP, Technical OperationsReveal Email/Phone
10
VP, CMCReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M1-50%N/AN/A
#3
$5.1M3322%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M2-60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
N/A1110%N/AN/A
#10
$5.4M290%N/AN/A
Add Company

What Is Verastem?

Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company focused on developing medicines to improve survival and quality of life of cancer patients. Our portfolio consists of small molecule kinase inhibitors that inhibit critical signaling pathways, which promote cancer cell survival and tumor growth. Our people are inspired by the strength, tenacity and courage of those battling cancer. Verastem team is anchored by core values of character, urgency, respect, and excellence. We pride ourselves in being an organization committed to diversity and inclusion in order to achieve and sustain excellence. We believe that empowering employees is what makes them truly care about the important work they do. To join our team or for more information, please visit www.verastem.com. Twitter: @VerastemOncolog

keywords:N/A

N/A

Total Funding

106

Number of Employees

$17.1M

Revenue (est)

19%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Verastem News

2022-04-19 - Verastem (VSTM) – Investment Analysts' Weekly Ratings Updates

4/14/2022 – Verastem is now covered by analysts at Royal Bank of Canada. They set an “outperform” rating and a $5.00 price target on the stock.

2022-04-17 - Verastem: Time To Take My Position Out Of Mothball

Verastem secured up to $150M in non-dilutive funding from Oxford Finance. Now, the company expects their cash runway to last through 2025. The...

2022-03-30 - Verastem Oncology Announces Inducement Grants Under Nasdaq ...

Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a development-stage biopharmaceutical company committed to the development and...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.5M1085%N/A
#2
$29.7M1105%$10M
#3
$23.2M11219%N/A
#4
$15.8M113-4%$49.5M
#5
$38.3M127-8%N/A